EQL Pharma ABOSTO:EQL -2.32%42 EBITDA Margin % is 4.26% as of Mar. 2026, which is 63% below its 10-year median of 11.62. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 954 Drug Manufacturers companies, EQL Pharma AB ranks worse than 52.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. EQL Pharma AB's EBITDA for the
three
months ended in Mar. 2026 was kr5.1 Mil. EQL Pharma AB's Revenue for the
three
months ended in Mar. 2026 was kr120.2 Mil. Therefore, EQL Pharma AB's EBITDA margin for the quarter that ended in Mar. 2026 was 4.26%.
EQL Pharma AB (OSTO:EQL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
EQL Pharma AB EBITDA Margin % Related Terms
EQL Pharma AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a EBITDA Margin % of 4.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EQL Pharma AB and its competitors. This is 63% below median its historical median of 11.62. Over the past decade, EQL Pharma AB's EBITDA Margin % has ranged from 3.74 to 18.13. According to the industry distribution chart, EQL Pharma AB ranks #504 out of 954 companies in the Drug Manufacturers industry, placing it in the top 52.8%.
Is EQL Pharma AB's EBITDA Margin % too high?
EQL Pharma AB's current EBITDA Margin % of 4.26% is 63% below median its 10-year median of 11.62. Over the past 10 years, this metric has ranged from a low of 3.74 to a high of 18.13. The Drug Manufacturers industry median EBITDA Margin % is 12.52. EQL Pharma AB's value of 4.26% is 66% below this industry median. Based on the distribution chart, EQL Pharma AB ranks #504 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #504 out of 954 companies for EBITDA Margin %. This places EQL Pharma AB in the lower half of its industry. The industry median EBITDA Margin % is 12.52. EQL Pharma AB's value of 4.26% is 66% below this benchmark. Historically, EQL Pharma AB's own EBITDA Margin % has ranged from 3.74 to 18.13 over the past decade. While the company's 10-year median is 11.62 vs. the industry median of 12.52, EQL Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current EBITDA Margin % of 4.26% is 66% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current EBITDA Margin % is 4.26%, which is 63% below median its own 10-year median of 11.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current EBITDA Margin % of 4.26%. The current EBITDA Margin % is 4.26%, which is 63% below median its 10-year median of 11.62 and 66% below the Drug Manufacturers industry median of 12.52. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current EBITDA Margin % is 4.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
